• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

冈比亚锥虫对戊烷脒耐药的遗传标记和印度次大陆内脏利什曼病患者戊烷脒治疗失败。

Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent.

机构信息

Department of Biomedical Sciences, Institute of Tropical Medicine Antwerp, Belgium.

出版信息

J Infect Dis. 2012 Sep 1;206(5):752-5. doi: 10.1093/infdis/jis424. Epub 2012 Jun 29.

DOI:10.1093/infdis/jis424
PMID:22753945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4125624/
Abstract

The current standard to assess pentavalent antimonial (SSG) susceptibility of Leishmania is a laborious in vitro assay of which the result has little clinical value because SSG-resistant parasites are also found in SSG-cured patients. Candidate genetic markers for clinically relevant SSG-resistant parasites identified by full genome sequencing were here validated on a larger set of clinical strains. We show that 3 genomic locations suffice to specifically detect the SSG-resistant parasites found only in patients experiencing SSG treatment failure. This finding allows the development of rapid assays to monitor the emergence and spread of clinically relevant SSG-resistant Leishmania parasites.

摘要

目前评估五价锑（SSG）对利什曼原虫敏感性的标准是一种繁琐的体外检测方法，其结果几乎没有临床价值，因为在 SSG 治愈的患者中也发现了 SSG 耐药寄生虫。通过全基因组测序确定的具有临床相关性的 SSG 耐药寄生虫候选遗传标记，在此基础上对更大的一组临床菌株进行了验证。我们表明，仅需 3 个基因组位置即可特异性检测到仅在 SSG 治疗失败的患者中发现的 SSG 耐药寄生虫。这一发现为监测具有临床相关性的 SSG 耐药利什曼原虫寄生虫的出现和传播提供了快速检测方法。

相似文献

1
Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent.冈比亚锥虫对戊烷脒耐药的遗传标记和印度次大陆内脏利什曼病患者戊烷脒治疗失败。
J Infect Dis. 2012 Sep 1;206(5):752-5. doi: 10.1093/infdis/jis424. Epub 2012 Jun 29.
2
Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.载硬脂胺的脂质体中的葡萄糖酸锑钠治疗使 BALB/c 小鼠对 SSG 耐药的杜氏利什曼原虫产生治愈作用。
PLoS One. 2011 Mar 10;6(3):e17376. doi: 10.1371/journal.pone.0017376.
3
Genetic markers for antimony resistant clinical isolates differentiation from Indian Kala-azar.用于区分印度黑热病抗锑临床分离株的遗传标记。
Acta Trop. 2016 Dec;164:177-184. doi: 10.1016/j.actatropica.2016.09.012. Epub 2016 Sep 11.
4
Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.阳离子脂质体葡萄糖酸锑钠（SSG），一种用于治疗对SSG敏感和耐药的杜氏利什曼原虫感染的有效治疗工具。
Antimicrob Agents Chemother. 2015 Jan;59(1):344-55. doi: 10.1128/AAC.03305-14. Epub 2014 Nov 3.
5
Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?内脏利什曼病的锑剂治疗：当前的体外药敏试验是否足以预测体内治疗结果？
Microbes Infect. 2007 Apr;9(4):529-35. doi: 10.1016/j.micinf.2007.01.009. Epub 2007 Jan 27.
6
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.印度黑热病野外分离株对葡萄糖酸锑钠治疗的耐药性在体外和体内实验模型中持续存在。
Parasitol Res. 2005 Jun;96(4):216-23. doi: 10.1007/s00436-005-1339-1. Epub 2005 May 3.
7
Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India.评估来自印度的对锑敏感和耐药的利什曼原虫临床分离株中的水甘油通道蛋白基因状态和表达谱。
J Antimicrob Chemother. 2010 Mar;65(3):496-507. doi: 10.1093/jac/dkp468. Epub 2010 Jan 12.
8
Leishmania donovani: genetic diversity of isolates from Sudan characterized by PCR-based RAPD.杜氏利什曼原虫：基于 PCR 的 RAPD 技术对苏丹分离株遗传多样性的研究。
Exp Parasitol. 2010 Aug;125(4):389-93. doi: 10.1016/j.exppara.2010.03.008. Epub 2010 Mar 25.
9
Activity of rutin, a potent flavonoid against SSG-sensitive and -resistant Leishmania donovani parasites in experimental leishmaniasis.芦丁，一种强效类黄酮，对 SSG 敏感和耐药的杜氏利什曼原虫在实验性利什曼病中的活性。
Int Immunopharmacol. 2018 Nov;64:372-385. doi: 10.1016/j.intimp.2018.09.026. Epub 2018 Sep 21.
10
Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden.杜氏利什曼原虫中的锑耐药性与体内寄生虫负担增加有关。
PLoS One. 2011;6(8):e23120. doi: 10.1371/journal.pone.0023120. Epub 2011 Aug 1.

引用本文的文献

1
Combination Therapy for Post-Kala-Azar Dermal Leishmaniasis: A Literature Review of Current Evidence.黑热病后皮肤利什曼病的联合治疗：当前证据的文献综述
Indian J Dermatol. 2024 Sep-Oct;69(5):396-405. doi: 10.4103/ijd.ijd_612_22. Epub 2024 Oct 29.
2
Antimony susceptible : evidence from drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.锑敏感：来自前米替福新时代和后米替福新时代间，从卡拉巴肿后皮肤利什曼病患者分离的寄生虫药物敏感性获得的证据。
Microbiol Spectr. 2024 Jun 4;12(6):e0402623. doi: 10.1128/spectrum.04026-23. Epub 2024 May 7.
3
In-depth comparison of cell-based methodological approaches to determine drug susceptibility of visceral Leishmania isolates.深入比较基于细胞的方法学方法，以确定内脏利什曼原虫分离物的药物敏感性。
PLoS Negl Trop Dis. 2019 Dec 2;13(12):e0007885. doi: 10.1371/journal.pntd.0007885. eCollection 2019 Dec.
4
Reverse Epidemiology: An Experimental Framework to Drive Biomarker Discovery by Functional Genetic Screening Using Relevant Animal Models.反向流行病学：通过使用相关动物模型进行功能遗传筛选来推动生物标志物发现的实验框架。
Front Cell Infect Microbiol. 2018 Sep 19;8:325. doi: 10.3389/fcimb.2018.00325. eCollection 2018.
5
Evaluating drug resistance in visceral leishmaniasis: the challenges.评估内脏利什曼病的耐药性：挑战
Parasitology. 2018 Apr;145(4):453-463. doi: 10.1017/S0031182016002031. Epub 2016 Nov 21.
6
Plasticity of the genome leading to gene copy number variations and drug resistance.基因组可塑性导致基因拷贝数变异和耐药性。
F1000Res. 2016 Sep 20;5:2350. doi: 10.12688/f1000research.9218.1. eCollection 2016.
7
Preclinical Studies Evaluating Subacute Toxicity and Therapeutic Efficacy of LQB-118 in Experimental Visceral Leishmaniasis.评估LQB-118对实验性内脏利什曼病的亚急性毒性和治疗效果的临床前研究
Antimicrob Agents Chemother. 2016 May 23;60(6):3794-801. doi: 10.1128/AAC.01787-15. Print 2016 Jun.
8
Successful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN-γ, but not IL-10 Production.人类内脏利什曼病的成功治疗可恢复抗原特异性干扰素-γ的产生，但不能恢复白细胞介素-10的产生。
PLoS Negl Trop Dis. 2016 Mar 10;10(3):e0004468. doi: 10.1371/journal.pntd.0004468. eCollection 2016 Mar.
9
Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain.杜氏利什曼原虫临床分离株及其实验衍生的对巴龙霉素耐药菌株的相对适合度
PLoS One. 2015 Oct 15;10(10):e0140139. doi: 10.1371/journal.pone.0140139. eCollection 2015.
10
A Multiplatform Metabolomic Approach to the Basis of Antimonial Action and Resistance in Leishmania infantum.一种基于多平台代谢组学方法研究婴儿利什曼原虫中锑剂作用及耐药性的基础
PLoS One. 2015 Jul 10;10(7):e0130675. doi: 10.1371/journal.pone.0130675. eCollection 2015.

本文引用的文献

1
Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex.全基因组 SNP 和微卫星变异揭示利什曼原虫复合种的人群水平流行病学。
Infect Genet Evol. 2012 Jan;12(1):149-59. doi: 10.1016/j.meegid.2011.11.005. Epub 2011 Nov 20.
2
Use of antimony in the treatment of leishmaniasis: current status and future directions.锑在利什曼病治疗中的应用：现状与未来方向。
Mol Biol Int. 2011;2011:571242. doi: 10.4061/2011/571242. Epub 2011 Jun 8.
3
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance.对多个利什曼原虫临床分离株的全基因组测序为了解种群结构和耐药机制提供了线索。
Genome Res. 2011 Dec;21(12):2143-56. doi: 10.1101/gr.123430.111. Epub 2011 Oct 28.
4
Leishmania antimony resistance: what we know what we can learn from the field.利什曼原虫锑剂耐药性：我们所知与可从该领域借鉴之处。
Parasitol Res. 2011 Nov;109(5):1225-32. doi: 10.1007/s00436-011-2555-5. Epub 2011 Jul 29.
5
Linking in vitro and in vivo survival of clinical Leishmania donovani strains.临床感染杜氏利什曼原虫株的体外和体内生存关联性研究。
PLoS One. 2010 Aug 17;5(8):e12211. doi: 10.1371/journal.pone.0012211.
6
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?内脏利什曼病：诊断、治疗和控制方面有哪些需求？
Nat Rev Microbiol. 2007 Nov;5(11):873-82. doi: 10.1038/nrmicro1748.
7
Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome?内脏利什曼病的锑剂治疗：当前的体外药敏试验是否足以预测体内治疗结果？
Microbes Infect. 2007 Apr;9(4):529-35. doi: 10.1016/j.micinf.2007.01.009. Epub 2007 Jan 27.
8
Direct detection of Mycobacterium tuberculosis complex DNA and rifampin resistance in clinical specimens from tuberculosis patients by line probe assay.采用线性探针分析法直接检测结核病患者临床标本中的结核分枝杆菌复合群DNA及利福平耐药性。
J Clin Microbiol. 2006 Dec;44(12):4384-8. doi: 10.1128/JCM.01332-06. Epub 2006 Oct 11.
9
Epidemiological dynamics of antimonial resistance in Leishmania donovani: genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal.杜氏利什曼原虫抗锑性的流行病学动态：基因分型揭示了来自尼泊尔的天然抗性临床分离株中的多克隆群体结构。
Infect Genet Evol. 2007 Mar;7(2):206-12. doi: 10.1016/j.meegid.2006.08.005. Epub 2006 Sep 27.
10
Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.尼泊尔东南部内脏利什曼病的治疗：葡萄糖酸锑钠疗效降低及制定政策限制疗效进一步下降的必要性
Trans R Soc Trop Med Hyg. 2003 May-Jun;97(3):350-4. doi: 10.1016/s0035-9203(03)90167-2.